[Pharmaceuticals can be cost-effective in the long run]

Lakartidningen. 2010 Apr;107(16):1081-5.
[Article in Swedish]
No abstract available

MeSH terms

  • Antibodies, Monoclonal / economics
  • Antibodies, Monoclonal / therapeutic use
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents / economics*
  • Antineoplastic Agents / therapeutic use
  • Benzamides
  • Breast Neoplasms / drug therapy
  • Cost-Benefit Analysis
  • Drug Costs
  • Female
  • Health Care Costs
  • Humans
  • Imatinib Mesylate
  • Lung Neoplasms / drug therapy
  • Male
  • Piperazines / economics
  • Piperazines / therapeutic use
  • Prostatic Neoplasms / drug therapy
  • Protein Kinase Inhibitors / economics
  • Protein Kinase Inhibitors / therapeutic use
  • Pyrimidines / economics
  • Pyrimidines / therapeutic use
  • Trastuzumab

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents
  • Benzamides
  • Piperazines
  • Protein Kinase Inhibitors
  • Pyrimidines
  • Imatinib Mesylate
  • Trastuzumab